Overview
- The consortium, led by the Hospital Nacional de Parapléjicos in Toledo under Dr. Jorge Collazos, is developing a device that aims to repair traumatic spinal cord injuries.
- DREIMS is a Class III bioelectrical implant that integrates electroconductive microfibers with protein coatings, an antifibrotic drug‑eluting hydrogel, and an implantable electrical stimulator to promote neural reconnection.
- Preclinical studies in a contusion model in pigs have produced encouraging results aligned with regulator‑oriented preclinical quality standards.
- The project has reached TRL 4–5 with €2.5 million in European Innovation Council funding, positioning regulatory‑grade manufacturing and clinical validation as the next steps.
- The team is seeking biotech venture funds, institutional investors, health‑focused angels, or medical device companies to finance production and pursue first‑in‑human studies targeted from 2028.